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Abstract
Background: The results of previous studies on the effect of low-dose aspirin in frozen-
thawed embryo transfer (FET) cycles are limited and controversial.
Objective: To evaluate the effect of low-dose aspirin on the clinical pregnancy in the
FET cycles.
Materials and Methods: This study was performed as a randomized clinical trial from
May 2018 to February 2019; 128 women who were candidates for the FET were
randomly assigned to two groups receiving either 80 mg oral aspirin (n = 64) or no
treatment. The primary outcome was clinical pregnancy rate and secondary outcome
measures were the implantation rate, miscarriage rate, and endometrial thickness.
Results: The endometrial thickness was lower in patients who received aspirin
in comparison to the control group. There were statistically significant differences
between the two groups (p = 0.018). Chemical and clinical pregnancy rates and abortion
rate was similar in the two groups and there was no statistically significant difference.
Conclusion: The administration of aspirin in FET cycles had no positive effect on the
implantation and the chemical and clinical pregnancy rates, which is in accordance with
current Cochrane review that does not recommend aspirin administration as a routine
in assisted reproductive technology cycles.
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1. Introduction
Human reproduction depends on a successful
implantation and the development of an embryo on
the endometrial surface. A receptive endometrium
is a main factor for embryo implantation. Adjuvant
therapy has been utilized to improve the thickness
and vascularity of the endometrium with the
purpose of improving implantation rates. One
of this adjuvant therapies is low-dose aspirin
administration (1).
There have been several studies on the effect
of low-dose aspirin in assisted reproductive
technology (ART) cycles, but contradictory and
limited results have been reported on the effect of
aspirin on the endometrial thickness as well as on
the frozen-thaw embryo transfer (FET) cycles (2, 3).
Several studies showed that there was a direct
correlation between an increased uterine vascular
resistance and decreased endometrial and sub-
endometrial blood flow with poor implantation and
pregnancy rate (4-6). Aspirin can inhibit platelet
aggregation and increases blood flow by changing
the balance between thromboxane (which is a
vasoconstrictor mediator) and prostaglandin (which
is vasodilator mediator) (1). As per the recent
studies, low-dose aspirin appears to be safe and
well-tolerated by pregnant women (7, 8). Other
aspirin mechanism is increasing it in the level of
integrin B3 and Leukemia inhibitory factor (LIF)
expression in the endometrium (9).
In a meta-analysis Wang and colleagues
suggested that “low-dose aspirin may increase
the pregnancy rate in In vitro fertilization/intra
cytoplasmic sperm injection (IVF/ICSI) and
recommended 100 mg/day ASA clinical use.
Because of the limitation of the included
studies, more well-designed large-scaled RCTs
(randomized clinical trial) are necessary to confirm
the effect of aspirin on the endometrial thickness
in the FET cycles” (10).
Madani and colleagues performed a pilot clinical
trial, where 60 patients who were candidates for
FET cycle were divided into two groups. Group
A received 100 mg aspirin orally and the other
group received placebo. Finally, they reported
that the administration of aspirin in FET cycles
improved implantation rate, clinical pregnancy
rate, and live birth rate. They also recommended
that a large sample size is also necessary to
confirm the effect of aspirin on the FET cycles
(11). Fatemi and colleagues , on the other hand
in a review study reported contradictory results
about the effect of aspirin on the IVF cycles
(12). Haapsamo and colleagues, reported that the
administration of aspirin in ovarian stimulation
cycles improved uterine hemodynamic status
compared to the control group (13). In another
study, the authors showed that the administration
of aspirin in patients undergoing IVF cycle reduced
uterine artery pulsatility index (PI) in the early
and mid-pregnancy and reduced the risk of
preeclampsia and intrauterine growth restriction
(IUGR) (14).
In a systematic review, researchers concluded
that there is insufficient evidence for routine
administration of aspirin in IVF cycles. On the
other hand, they reported that the administration
of aspirin has no positive significant effects on
IVF outcome and needs further studies (15). Dirckx
and co-worker in Belgium found no positive effect
of aspirin in improving clinical pregnancy in IVF
cycles and recommended that it should not be
used routinely (3). Also, in a recent Cochrane
review, the authors concluded that the use of
empirical aspirin for general IVF population cannot
be recommended for routine use (16).
Based on the contradictory results and the lack
of sufficient studies on the effect of aspirin on the
pregnancy rate in FET, in our study we aimed to
investigate the effect of low-dose aspirin adjuvant
therapy in women undergoing FET cycles.
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2. Materials and Methods
This study was a randomized clinical trial
performed in the Research and Clinical Center
for Infertility, Yazd Reproductive Sciences Institute
from January 2019 to February 2020.
The inclusion criteria were age <40 yr, at
least two frozen-thawed embryos available
for another transfer, no contraindications for
aspirin administration, no uterine disorders, no
endometriosis, no history of uterine surgery, and
no history of recurrent abortion (two or more than
two abortions).
128 eligible women who were assigned for FET
participated in the study. They were allocated into
two groups randomly and equally. Group A (n = 64)
was prescribed 80 mg aspirin, and for group B
(n = 64), no treatment was prescribed to the routine
FET protocols (Table I).
First, all patients underwent transvaginal
ultrasonography on the second day of their
cycles for excluding functional ovarian cysts. For
endometrial preparation, patients received 6 mg
estradiol valerate (aburahan co.) per day from
second day of their cycles, and if the endometrial
thickness was 7 mm or less on the thirteenth day
of their cycles, the dose was increased to 10 mg.
When the optimal endometrial thickness
(>8 mm) was obtained, vaginal progesterone
400 mg BID was started and continued until the
12 week of pregnancy. For endometrial thickness
measurement, transvaginal ultrasonography (fillips
affinity 70) was performed from the 13th day of
their cycles and every 4 days if the endometrial
thickness of 8 mm was not obtained on the 13th
day.
The two selected embryos were transferred at
cleavage stage by Cook catheter. 5000 IU HCG
(human chorionic gonadotropin) was administered
on the first, third, and sixth days of embryo transfer.
In our study 20 days after the embryo transfer
beta human chorionic gonadotropin (βHCG)
was checked. The primary outcome was clinical
pregnancy rate that determined as presence of
an intrauterine gestational sac with fetal heart
beat (28-42 days after the embryo transfer). We
requested women to continue taking aspirin for
until 12 weeks of gestation. Secondary outcomes
were implantation and miscarriage rates. The
implantation rate was determined as the total
number of gestational sacs per total number of
transferred embryos, and the miscarriage rate was
determined as the number of miscarriage that took
place until the 20th week of pregnancy.
Table I. Basic patient characteristics and clinical parameters in two study groups
Variables ASA group (n = 63) Control group (n = 62) P-value
Age (Yr)* 29.48 ± 4.78 29.65 ± 4.52 0.835
BMI (kg/m2)*
≤ 24.9 20 (31.25) 16 (25.00)
25-29.9 30 (46.88) 38 (59.37)
≥ 30 14 (21.87) 10 (15.62)
0.106
Duration of infertility (Yr)* 7.09 ± 3.49 7.37 ± 3.70 0.659
Number of previous embryo transfer cycles **
1 39 (60.9) 35 (54.7)
2 23 (35.9) 25 (39.1)
3 2 (3.1) 4 (6.2)
0.369
Cycle cancellation rate ** 1 (1.6%) 2 (3.1) 1.00
Endometrial thickness (mm)* 8.64 ± 1.60 9.29 ± 1.70 0.028*
*Data presented as Mean ± SD (Student t test)
** Data presented as n (%) (chi-square test)
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2.1. Ethical consideration
The study has been approved by the
ethical committee of the Yazd Reproductive
Sciences Institute (IR.SSU.RSI.REC.1398.003).
All participants gave informed consent being
included in the study.
2.2. Statistical analysis
Data were analyzed using the Statistical
Package for the Social Sciences 15.0 software.
The baseline characteristics of the two groups of
patients were compared using the student t test.
Differences in the pregnancy outcomes of the two
groups were analyzed using the Chi-square test.
P ≤ 0.05 was considered statistically significant.
3. Results
In the present study, from 700 women who
candidate for FET 572 were excluded from
our study and we evaluated a total of 128
patients in two study groups: 64 cases in
ASA (amino salicylic acid) group and 64 in
control group. There was one cancelled cycle
in case group (1/64) and two in control group
(2/64) due to thin endometrium (< 7 mm)
(Figure 1). As shown in table I, the age, BMI,
infertility duration, and the number of previous
embryo transfer cycles had similarity in the two
study groups, and there was no statistically
significant difference between the two groups.
The endometrial thickness was lower in the
group receiving ASA in comparison to the control
group. The difference was statistically significant
between the two groups (p = 0.028; Table I).
ART outcomes in the two study groups are
summarized in table II. The quality of transferred
embryo was similar in the two groups and
the highest number of embryos were in good
quality (A and B). In all cycles, we transferred
two embryo. From 126 transferred embryo in
case group, 16 pregnancy sacs were observed
in ultrasonography, and from 124 transferred
embryo in control group, 18 pregnancy sacs were
observed in ultrasonography. The Implantation
rate was higher in the control group (14.5% vs.
12.6%), but this difference was not statistically
significant. Chemical and clinical pregnancy rates
were similar in the two groups, and there was no
statistically significant difference.
Table II. ART outcome in two study groups
Variables ASA group (n = 63) Control group (n = 62) P-value
Embryo quality*
A 8 (12.7) 15 (24.2)
B 38 (60.3) 32 (51.6)
C 17 (27.0) 15 (24.2)
0.251
Implantation rate* 16/126 (12.69) 18/124 (14.51) 0.759
Chemical pregnancy rate* 19 (30.2) 15 (24.2) 0.547
Clinical pregnancy rate* 15 (23.8) 12 (19.4) 0.665
Abortion/clinical pregnancy** 0/15 0/12
* Data presented as n (%). chi-square test ** data presented as n (%)
Note: Data obtained by descriptive statistics; data presented number (%); P ≤ 0.05 considered statistically significant
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Enrollment 
Lost to follow-up (patient request) (n = 0) 
ØDiscontinued intervention (give reasons) (n = 1)* 
Follow-Up 
Allocated to intervention (n = 64) 
ØReceived allocated intervention (n = 64) 
ØDid not receive allocated intervention (give 
reasons) (n = 0) 
 
Allocated to intervention (n = 64) 
ØReceived allocated intervention (n = 64) 
ØDid not receive allocated intervention (give reasons) 
(n = 0) 
 
Allocation 
Assessed for eligibility (n = 700) 
Excluded (n = 572) 
ØNot meeting inclusion criteria (n = 570) 
ØDeclined to participate (n = 0) 
ØOther reasons (n = 2) 
Lost to follow-up (patient request) (n = 0) 
ØDiscontinued intervention (give reasons) (n = 0.2)* 
Randomized (n = 128) 
Analysed (n = 62) 
ØExcluded from analysis (give reasons) (n = 0) 
Analysis 
Analysed (n = 63) 
ØExcluded from analysis (give reasons) (n  = 0) 
Figure 1. Consort flow chart.
4. Discussion
The results of our study showed that there was
no difference in the pregnancy outcome and the
clinical pregnancy rate in patients who received
aspirin in comparison with the control group in
patients undergoing FET cycles. The endometrial
thickness was significantly lower in the aspirin
group than the control group. Some studies have
investigated the role of aspirin in ART cycles and
reported contradictory results (17, 18).
The majority of previous studies investigated
the role of aspirin as an adjuvant therapy on ART
outcome in fresh cycles (stimulated cycles) (17,
19). In fresh cycles, the estradiol levels are higher
than in the freeze-thaw cycles. Also, in a fresh
cycle, embryo is exposed to supra-physiological
levels of estrogen during implantation but in
the frozen-thaw cycles endometrial preparation
is done artificially by estrogen and progesterone
administration and the embryo is not exposed
to supra-physiological level of estrogen. Supra-
physiologic levels of estrogen may have a
negative impact on endometrial receptivity and
maybe responsible for implantation failure in
ART (20, 21). Therefore, the results of aspirin
adjuvant therapy in the fresh and frozen cycles are
noncomparable. The results of the past studies on
the effect of low-dose aspirin in FET cycles are
limited.
The result of ART outcome in the present
study was in contrast with Madani’s study. They
reported that the administration of aspirin in
FET cycles improved the implantation, clinical
pregnancy, and live birthrates, however, we found
no statistically significant improvement in the
biochemical, clinical pregnancy, and abortion
rates in the aspirin group in comparison with the
control. However, their study was a pilot study and
the difference between the results of our study
and the Madani’s study may be the low sample
size of their study (11).
Hsieh and colleagues showed higher clinical
pregnancy rate and better endometrial pattern
in patients with thin endometrium after aspirin
administration, and because in this group they
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selected patients who had thin endometrium their
results is in contrast to our findings (22).
Conforming to our study, a meta-analysis (15)
and reports by Cochrane reviews (16, 23) also
establish that there was no improvement in
pregnancy rates with the use of low-dose aspirin.
Jeromeh demonstrated that the clinical pregnancy
rate was lower in the aspirin group compared
with control group (11.1% vs 33.3% respectively)
for, and the implantation rates were 2.9 and
10.9%, respectively. In this study, low-dose aspirin
administration did not cause positive effect on
pregnancy rates in FET cycles (24). Gelbaya and
co-workers suggested that in FET cycles, there
was no significant difference in pregnancy rate
between untreated women with normal uterine
perfusion and those that uterine perfusion was
improved after aspirin administration. This result
is similar with our study (25). In another study,
Doppler ultrasoundwas used for uterine perfusion
assessment and patients were classified as two
groups: normal uterine perfusion and impaired
uterine perfusion. administration of low-dose
aspirin to hormone replacement therapy inwomen
with impaired uterine perfusion was associated
with improved uterine perfusion and acceptable
pregnancy rates but without any benefits in
patients with normal perfusion (26). In our study,
the assessment of uterine perfusion and patients
classification was not done.
5. Conclusion
Our study concludes that the administration
of aspirin in frozen-thaw cycles had no positive
effect on the implantation, chemical, and clinical
pregnancy rates, and is in accordance with
the current Cochrane review that does not
recommend aspirin administration as a routine in
ART cycles.
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